Glaukos (GKOS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

GKOS Glaukos

Watchlist

112.210
+3.060+2.80%

Close Mar 4 16:00 ET

112.210
0.0000.00%

Post 16:17 ET

6.35BMarket Cap-40.51P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts?
Yahoo Finance23:52 ET
Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $160
Moomoo NewsMar 4 09:31 ET · Ratings
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $175
Moomoo NewsMar 3 07:31 ET · Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Glaukos (GKOS)
TipRanksMar 3 06:56 ET · Ratings
Glaukos Insider Sold Shares Worth $2,497,335, According to a Recent SEC Filing
MT NewswiresMar 3 02:55 ET
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
Zacks Feb 28 09:05 ET

Comments

Teddy123

Feb 24 06:16

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa

$Glaukos (GKOS.US)$
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery?

Moomoo AI

Jan 21, 2024 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.